Biotech Values

[mcbio]

ACHN:

Nice call almost dead on with the over allotment

finance.yahoo.com/news/Achillion-Pharmaceuticals-pz-3218301572.html?x=0&.v=1

Well, well, well. About time ACHN. Great move for them though. That said, this raise does solidify my belief that they're not on the cusp of partnering ACH-1625 and/or ACH-2684 any time soon (or otherwise being taken out). I still think they at least need positive 3-month Phase 2b data from 1625 at the end of this year before they possibly get some serious interest on either front. Even then, there's always the possibility that it may take some hiccup with one or both of the VRUS nukes before this occurs. Will the buzz continue to grow that the VRUS nukes alone may be a sufficient 2nd/3rd gen HCV treatment? I still bet that there will be a sizeable enough opportunity for a 2nd/3rd gen HCV PI down the road (especially in light of ACHN's relatively small market cap), but will the continued buzz for the VRUS nukes alone dampen investors' confidence in this scenario? (If there is any hiccup with one or both of the VRUS nukes and ACHN shows positive Phase 2b data for 1625 and is somewhere in the ballpark of current valuation, I'll be quite interested in going long again. For the time being, ACHN remains on my watchlist.)